Search
squalamine phosphate (ENT-01)
Indications:
- treatment of constipation in patients with Parkinson's disease (investigational)
- may improve cognition in patients with Parkinson's disease [1]
Dosage:
- 250 mg PO QD
- starting dose may be lower, optimal dose may be higher
Adverse effects:
- nausea (34%)
- diarrhea (19%)
Mechanism of action:
- inhibits formation of alpha-synuclein in enteric neurons
General
gastrointestinal agent
squalamine
Database Correlations
PUBCHEM cid=86653613
References
- Camilleri M et al.
Oral ENT-01 targets enteric neurons to treat constipation in Parkinson disease:
A randomized controlled trial.
Ann Intern Med 2022 Nov 8; [e-pub].
PMID: 36343348
https://www.acpjournals.org/doi/10.7326/M22-1438